Hypertension after kidney transplantation: Impact, pathogenesis and therapy

American Journal of the Medical Sciences

Volumn 325, Issue 4, 2003, Pages 202-208

  Zhang, Rubin ^a   Leslie, Bruce ^a   Boudreaux, J Philip ^a   Frey, Daniel ^a   Reisin, Efrain ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Cardiovascular disease; Chronic allograft nephropathy; Drug therapy; Hypertension; Kidney transplantation

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOSPORIN A; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IMMUNOSUPPRESSIVE AGENT; ISRADIPINE; LISINOPRIL; LOOP DIURETIC AGENT; LOSARTAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICARDIPINE; NIFEDIPINE; PERINDOPRIL; QUINAPRIL; TACROLIMUS; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VASODILATOR AGENT; VERAPAMIL;

ANGIONEUROTIC EDEMA; ANIMAL MODEL; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL; CONFERENCE PAPER; CORTICOSTEROID THERAPY; COUGHING; CROSSOVER PROCEDURE; DISEASE COURSE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DYSLIPIDEMIA; GINGIVA HYPERPLASIA; GRAFT SURVIVAL; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN RESISTANCE; KIDNEY ARTERY STENOSIS; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEG EDEMA; NEPHROTOXICITY; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PROTEINURIA; RISK FACTOR;

EID: 0037390620     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200304000-00006     Document Type: Conference Paper

References (53)

1. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998;53:217-22.
2. Mange KC, Cizman B, Joffe M, et al. Arterial hypertension and renal survival. JAMA 2000;283:633-8.
3. Howard RJ, Patton PR, Reed AI, et al. The changing causes of graft loss and death after kidney transplantation. Transplantation 2002;73:1923-8.
4. Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000;57:307-13.
5. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999;341:1725-9.
6. Cosio FG, Pelletier RP, Pesavento TE, et al. Elevated blood pressure predicts the risk of acute rejection in renal allograft recipients. Kidney Int 2001;59:1158-64.
7. Midtvedt K, Ihlen H, Hartmann A, et al. Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: a prospective randomized double-blind study. Transplantation 2001;72:107-11.
8. Rigatto C, Foley RN, Kent GM, et al. Long-term changes in left ventricular hypertrophy after renal transplantation. Transplantation 2000;70:570-5.
9. Aakhus S, Dahl K, Wideroe TE. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant 1999;14:648-53.
10. Fernandez-Fresnedo G, Escallada R, Rodrigo E, et al. The risk of cardiovascular disease associated with proteinuria in renal transplant patients. Transplantation 2002;73:1345-8.
11. Rettig R, Bandelow N, Patschan O, et al. The importance of kidney in primary hypertension: insights from cross-transplantation. J Hum Hypertens 1996;10:641-4.
12. Strandgaard S, Hansen U. Hypertension in renal allograft recipients may be conveyed by cadaveric kidneys from donors with subarachnoid hemorrhage. Br Med J (Clin Res Ed) 1986;292:1041-5.
13. Curtis JJ, Luke RG, Diethelm AG, et al. Remission of essential hypertension after renal transplantation. N Engl J Med 1983;309:1009-13.
14. Guidi E, Menghetti D, Milani S, et al. Hypertension may be transplanted with the kidney in humans: a long-term historical prospective follow-up of recipients grafted with kidneys coming from donors with or without hypertension in their families. J Am Soc Nephrol 1996;7:131-8.
15. Brenner BM, Mackenzie HS. Nephron mass as a risk factor for progression of renal disease. Kidney Int Suppl 1997;52:S124-7.
16. Fervenza FC, Lafayette RA, Alfrey EJ, et al. Renal artery stenosis in kidney transplants. Am J Kidney Dis 1998;31:142-7.
17. Huysmans FT, Hoitsman FH, Koene RA. Factors determining the prevalence of hypertension after renal transplantation. Nephrol Dial Transplant 1987;2:34-9.
18. Bales GT, Fellner SK, Chodak GW, et al. Laparoscopic bilateral nephrectomy for renin-mediated hypertension. Urology 1994;43:874-7.
19. Grundfeid JP, Kleinknecht D, Moreau JF. Permanent hypertension after renal homotransplantation in man. Clin Sci Mol Med 1975;48:391-5.
20. Huysmans FT, van Heusden FH, Wetzels JF, et al. Antihypertensive effect of beta- blockade in renal transplant recipients with or without host kidneys. Transplantation 1988;46:234-8.
21. Tale SJ, Textor SC, Canzanello VJ, et al. Role of steroid dose in hypertension early in liver transplantation with tacrolimus and cyclosporine. Transplantation 1996;62:1588-92.
22. Veenstra DL, Best JH, Hornberger J, et al. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999;33:829-39.
23. Buell JF, Kulkarni S, Grewal HP, et al. Early corticosteroid cessation at one week following kidney transplant under tacrolimus and mycophenolate mofetil immunosuppression, three-year follow-up. Transplantation 2000;69:S134.
24. Campistol JM, Grinyo JM. Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephropathy. Transplantation 2001;71:SS42-51.
25. Haug C, Grill C, Schmic-Kotsas A, et al. Endothelin release by rabbit proximal tubule cells: modulatory effects of cyclosporine A, tacrohmus, HGF and EGF. Kidney Int 1998; 54:1626-31.
26. Lanese DM, Coger JD. Effects of endothelin receptor antagonism on cyclosporine-induced vasoconstriction in isolated rate renal arterioles. J Clin Invest 1993;91:2144-9.
27. Lassila M, Finckenberg P, Pere AK, et al. Comparison of enalapril and valsartan in cyclosporine A induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high sodium diet. Br J Pharmacol 2000;130:1339-43.
28. Shihab FS, Andoh TF, Tanner AM, ea al. Expression of apoptosis regulatory genes in chronic cyclosporine nephrotoxicity favors apoptosis. Kidney Int 1999;56:2147-51.
29. Shihab FS, Bennett WM, Tanner AM, et al. Angiotensin 2 blockade decreases TGF-beta 1 and matrix proteins in cyclosporine nephropathy. Kidney Int 1997;52:660-5.
30. Campistol JM, Inigo P, Jimenez W, et al. Losartan decreases plasma levels of TGF-beta 1 in transplant patients with chronic allograft nephropathy. Kidney Int 1999;56:714-9.
31. Perez Fontan M, Rodriguez-Carmona A, Garcia Falcon T, et al. Early immunologic and nonimmunologic predictors of arterial hypertension after renal transplantation. Am J Kidney Dis 1999;33:21-8.
32. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000;36:646-61.
33. Reisin E. Nonpharmacological approaches to hypertension: weight, sodium, alcohol, exercise and tobacco considerations. Med Clin North Am 1997;81:1289-303.
34. Odorico JS, Knechtle SJ, Rayhill SC, et al. The influence of native nephrectomy on the incidence of recurrent disease following renal transplantation for primary glomerulonephritis. Transplantation 1996;61:228-32.
35. Carozzi, Nasini MG, Pietrucci A, et al. Immunosuppressive effects of different calcium channel blockers in human kidney allografts. Transplant Proc 1995;27:1054-8.
36. Midtvedt K, Hartmann A, Foss A, et al. Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. Transplantation 2001;72:1787-97.
37. van Riemsdijk IC, Mulder PG, de Fijter JW, et al. Addition of isradipine results in a better renal function after kidney transplantation: a double-blind, randomized, placebo-controlled, multi-center study. Transplantation 2000;70:122-6.
38. Bakris GL. Renal effects of calcium antagonists in diabetes mellitus: an overview of studies in animal models and in humans. Am J Hypertens 1991, 4:487S-93S.
39. Ruggenenti P, Perrna A, Benini R, et al. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition and blood pressure control on chronic non-diabetic nephropathies. J Am Soc Nephrol 1998;9:2096-101.
40. Amuchastegui SC, Azzollini N, Mister M, et al. Chronic allograft nephropathy in the rats is improved by angiotensin 2 receptor blockage but not calcium channel antagonism. J Am Soc Nephrol 1998;9:1398-402.
41. Stigant CE, Cohen J, Vivera M, et al. ACE inhibitors and angiotensin 2 antagonists in renal transplantation: an analysis of safety and efficacy. Am J Kidney Dis 2000;35:58-63.
42. Sennesael J, Lamote J, Violet I, et al. Comparison of perindopril and amlodipine in cyclosporine-treated renal allograft recipients. Hypertension 1995;26:436-44.
43. Suwelack B, Gerhardt U, Hausberg M, et al. Comparison of quinapril versus atenolol: effects on blood pressure and cardiac mass after renal transplantation. Am J Cardiol 2000; 86:583-5.
44. Lin J, Valeri AM, Markowitz GS, et al. Angiotensin converting enzyme inhibition in chronic allograft nephropathy. Transplantation 2002;73:783-8.
45. Calvino J, Lens XM, Romero R, et al. Long-term anti-proteinuric effect of losartan in renal transplant recipients treated for hypertension. Nephrol Dial Transplant 2000;15:82-6.
46. Barnas U, Schnidt A, Haas M, et al. The effect of prolonged angiotensin-converting enzyme inhibition on excretory kidney function and proteinuria in renal allograft recipients with chronic progressive transplant failure. Nephrol Dial Transplant 1996;11:1822-6.
47. Klingbeil AU, Muller HJ, Delles C, et al. Regression of left ventricular hypertrophy by AT1 receptor blockade in renal transplant recipients. Am J Hypertens 2000;13:1295-300.
48. Hernandez D, Lacalzada J, Salido E, at al. Regression of left ventricular hypertrophy by lisinopril after renal transplantation: role of ACE gene polymorphism. Kidney Int 2000;58:889-97.
49. Hausberg M, Barenbrock M, Hohage H, et al. ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients. Hypertension 1999;33:862-8.
50. Mourad G, Vela C, Ribstein J, et al. Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy. Transplantation 1998;65:661-5.
51. Johnson R, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001;72:777-86.
52. Gregory CR, Huie P, Shorthouse P, et al. Treatment with rapamycin blocks arterial thickening following mechanic and alloimmune injury. Transplant Proc 1993;25:120-4.
53. Ojo AO, Meier-Kriesche HU, Handson JA et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000;69:2405-9.